Grifols has introduced its direct-to-consumer programme, AlphaID At Home Genetic Health Risk Service (AlphaID At Home), in the US.
The new programme will help screen for the genetic risk of alpha1-antitrypsin deficiency (alpha-1), which is also called genetic chronic obstructive pulmonary disease.
In November 2022, the US Food and Drug Administration (FDA) approved AlphaID At Home for direct-to-consumer use.
The test can screen for the most prevalently reported genetic mutations linked to alpha-1, including the S, Z, F and I alleles, as well as rare and null alleles.
It utilises the same precise genotyping test manufactured by the company and provided to physicians worldwide since 2018 for alpha-1 screening.
Grifols Diagnostic president Antonio Martínez said: “Given the fact that it can take several years until a patient with alpha-1 is properly diagnosed, AlphaID At Home can indicate someone’s risk for alpha-1 in a matter of weeks.”
AlphaID At Home is now accessible for ordering in the US at no cost via a secure online portal that complies with HIPAA standards.
After receiving the at-home screening kit, individuals can easily collect their saliva sample and send it to a laboratory adhering to the Clinical Laboratory Improvement Amendments standards for further processing.
Individuals can access their genetic results through a secure online portal after a few weeks.
Alpha-1 Foundation president and CEO Scott Santarella said: “We wholeheartedly support initiatives and innovations that contribute to the diagnosis of alpha-1. As leaders in alpha-1 testing, Grifols is doubling down on its commitment to the alpha-1 community by making it easier and more efficient to get diagnosed.”
<!-- GPT AdSlot 3 for Ad unit 'Verdict/Verdict_In_Article' ### Size: [[670,220]] -- !-- End AdSlot 3 -->- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoAiStream. Web3 Data Intelligence. Knowledge Amplified. Access Here.
- Minting the Future w Adryenn Ashley. Access Here.
- Buy and Sell Shares in PRE-IPO Companies with PREIPO®. Access Here.
- Source: https://www.medicaldevice-network.com/news/grifols-alphaid-at-home-programme/
- :has
- :is
- 2018
- 2022
- 220
- a
- access
- accessible
- Ad
- administration
- After
- also
- amendments
- and
- approved
- AS
- At
- by
- called
- CAN
- Cancer
- ceo
- Clinical
- collect
- commitment
- community
- company
- contribute
- Cost
- credit
- Disease
- doubling
- down
- drug
- easier
- easily
- efficient
- end
- fact
- fda
- few
- food
- Food and Drug Administration
- Food and Drug Administration (FDA)
- For
- Foundation
- further
- get
- Health
- help
- Home
- HTTPS
- i
- improvement
- in
- Including
- indicate
- individuals
- initiatives
- innovations
- Institute
- IT
- ITS
- jpg
- kit
- laboratory
- leaders
- linked
- Making
- manufactured
- Matter
- more
- more efficient
- most
- National
- New
- no
- November
- now
- of
- on
- online
- out
- patient
- plato
- Plato Data Intelligence
- PlatoData
- Portal
- precise
- president
- processing
- programme
- properly
- provided
- RARE
- receiving
- Reported
- Results
- Risk
- rolls
- s
- Said
- Saliva
- same
- Screen
- screening
- secure
- send
- service
- several
- Share
- since
- Size
- standards
- support
- Take
- test
- Testing
- that
- The
- their
- this
- Through
- to
- unit
- Unsplash
- until
- us
- use
- via
- Weeks
- WELL
- which
- wholeheartedly
- will
- with
- worldwide
- years
- zephyrnet
